1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • CheckMate 067: Long-term outcomes in patients with mucosal melanoma
    Meeting Abstract

    Shoushtari, A. N.; Wagstaff, J.; Ascierto, P. A.; Butler, M. O.; Lao, C. D.; Marquez-Rodas, I.; Chiarion-Sileni, V.; Dummer, R.; Ferrucci, P. F.; Lorigan, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study
    Meeting Abstract

    Sharman, J. P.; Brander, D. M.; Mato, A. R.; Ghosh, N.; Schuster, S. J.; Kambhampati, S.; Burke, J. M.; Lansigan, F.; Schreeder, M. T.; Lunin, S. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • CNS involvement by North American-ATLL (NA-ATLL) is associated with discrete patterns and molecular profile involving XPO1 E571 and KLF2/PI3KCD in selected cases
    Meeting Abstract

    Shah, N.; Patel, R. J.; Thakkar, A.; Rahman, S.; Acuna-Villaorduna, A.; Shah, U.; Herrera, D. A.; Slasky, S.; Gritsman, K.; Goldfinger, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Acquired resistance to PD-1 blockade in NSCLC
    Meeting Abstract

    Schoenfeld, A. J.; Rizvi, H.; Memon, D.; Luo, J.; Preeshagul, I. R.; Sauter, J. L.; Plodkowski, A. J.; Vanderbilt, C.; Miller, M. L.; Hellmann, M. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes
    Meeting Abstract

    Sassine, D.; Straubhar, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Kyi, C.; Leitao, M. M.; Mueller, J. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Kelly, C. M.; Kiesler, H.; Martindale, M.; Nicholls, C.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Baer, M. R.; Larson, R. A.; Fathi, A. T.; Yokoyama, H.; Hosono, N.; Hasabou, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save